Study of Tocilizumab with Endovascular Treatment for Acute Posterior Circulation Large Vessel Occlusion Stroke A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial

What this Trial Is About

Researchers are investigating the safety and effectiveness of combining an interleukin-6 receptor inhibitor called tocilizumab with endovascular therapy for patients who have acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial uses a randomized, double-blind, placebo-controlled design to assess whether adding tocilizumab can improve outcomes compared to endovascular treatment alone. The study is led by Capital Medical University and focuses on patients with this specific type of ischemic stroke. Participants will be randomly assigned to receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion is diluted to 100 mL and administered within 30 minutes after randomization, lasting more than one hour. The study will compare these two groups to evaluate the effects of the added tocilizumab treatment. During the study, researchers will monitor patients for 90 days, assessing their recovery using the modified Rankin Scale mRS to measure disability and function. Other assessments include neurological improvement at 24 hours, NIH Stroke Scale scores at 7 days or discharge, quality of life using EQ-5D-5L, and the Barthel Index for daily living activities. Safety and efficacy will be closely followed through clinical evaluations and standard laboratory tests throughout the trial period.

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke